This synthetic analogue of the inhibitory neurotransmitter γ-amino butyric acid (GABA) inhibits seizure activity via multiple mechanisms, including inhibition of neuronal sodium channels and potentiation of the release and action of GABA. It is well absorbed in dogs after oral administration and undergoes both hepatic and renal metabolism. In dogs, the initial dosage is 10–15 mg/kg, PO, tid. Higher dosages (30–60 mg/kg, PO, tid-qid) may be necessary but can produce sedation and ataxia. If excessive sedation occurs, a lower dose should be used initially and gradually increased. Therapeutic monitoring is not usually necessary with this drug. No drug interactions have been reported. Gabapentin has been used in cats at 5–10 mg/kg, bid-tid.